IPV BSL-3/polio containment guidelines (Feb 2003) - World Health ...

e) decontaminating equipment before removal from the facility for repair or
maintenance.
6.9 Data sheets and associated materials that have been used in live virus areas must be
disinfected upon exit from the containment facility, or an electronic data gathering
and transmission systems implemented to transfer data from the containment area.
Polio strains for BSL-3/polio containment
6.10 All wild type strains of live poliovirus are to be contained within BSL-3/polio
biosafety conditions, including strains commonly utilized for IPV production (e.g.
Mahoney, MEF-1, Saukett, Brunhilde, and Brunender strains)
6.11 Attenuated poliovirus strains (such as Sabin strains) that have been approved by the
national regulatory agency in the country of manufacture for use as an oral polio
vaccine, when used for manufacturing IPV, do not require containment in BSL-
3/polio facilities provided they are produced under conditions that would make
them suitable for oral vaccine use. If conditions other than those approved for
production of oral polio vaccine are used (e.g. different multiplicity of infection or
fermentation temperatures), it must be verified that the virus so produced poses no
28
Adopted by the 53 rd meeting of the WHO Expert Committee on Biological Standardization, 17-21 February 2003. A definitive
version of this document, which will differ from this version in editorial but not scientific detail, will be published in the WHO
Technical Report Series.